Clinical Trial

Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA

Study acronym: Ga-68-FAPI-46
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 22, 2025 (before its estimated April 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
This single-center, phase II clinical trial investigates the diagnostic efficacy of Ga-68-FAPI-46 PET scans in detecting colorectal cancer (CRC) recurrence during post-treatment surveillance, particularly in patients with elevated serum carcinoembryonic antigen (CEA). The study compares the sensitivity, specificity, and accuracy of Ga-68-FAPI-46 PET with the conventional F-18-FDG PET scans, aiming to enhance recurrence detection in CRC patients who underwent curative surgery. Thirty participants will be enrolled and monitored through imaging studies and clinical follow-up.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-06.
Trial Details
NCT Number NCT06769828
Lead Sponsor Koo Foundation Sun Yat-Sen Cancer Center
Conditions Colorectal Cancer Recurrent
Enrollment 30 participants
Start Date 2025-02-01
Primary Completion 2026-04-14 (estimated)
Study Completion 2026-04-14 (estimated)
Updated on ClinicalTrials.gov 2025-01-22